Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03748355|
Recruitment Status : Enrolling by invitation
First Posted : November 20, 2018
Last Update Posted : November 20, 2018
|Condition or disease||Intervention/treatment||Phase|
|Psychiatric Disorder||Genetic: Pharmacogentic Analysis||Not Applicable|
The Researchers are trying to learn more about how individuals break down and process medications based on their genes. The Researchers are doing this in order to assess the number of potential genotype-based drug interactions and side effects in patients with polypharmacy as well as to assess the number of potential individualized (based on the patient's genotype) drug interactions and side effects in these patients. After completing the OneOme genetic testing and relaying those results to the patients care team, the Researchers will then assess, at 30 days post-recommendations, whether the medication recommendations to reduce individualized drug interactions and adverse effects were followed, and (2) whether the adverse effects decrease compared to admission.
Patients will be recruited from the inpatient units listed in the inclusion criteria and, upon admission, each patient will complete a 24 item questionnaire measuring medication side effects, have a review of their medications for potential drug-drug and drug-genotype interactions (classified as low, medium or high risk), and then undergo the buccal swab to collect the DNA cells which will then be sent to OneOme for analysis. When the results are available, the study investigators will review the medications again for potential drug-drug and drug-genotype interactions and then communicate to the patients clinical team those results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
Thirty days after the recommendations are communicated to the patient's clinical team, the patient will be contacted by phone. During this phone call, the following information will be obtained:
- The patient's current medication list.
- The patient's 24 item questionnaire measuring medication side effects.
- The patient's one item self rating of improvement Once this phone call is completed, the research team will determine whether the medication recommendations were followed by the patient's clinical team, whether the adverse effects decreased compared to hospital admission, and whether the patient reported improvement.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects|
|Actual Study Start Date :||October 14, 2018|
|Estimated Primary Completion Date :||August 8, 2019|
|Estimated Study Completion Date :||September 8, 2019|
A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
Genetic: Pharmacogentic Analysis
Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
Other Name: OneOme Pharmacogentic Analysis
- Reduction of Potential Drug Interactions [ Time Frame: 30 days ]Reduction of potential drug interactions risk measured by the numbers in low, medium and high categories.
- Reduction of Side Effects [ Time Frame: 30 days ]Reduction of side effects as measured by side effects rating scale. Improvement of patient's self-assessment via the questionnaire item.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748355
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Simon Kung, MD||Mayo Clinic|